Cagrisema (Cagrilintide + Semaglutide) vs Pramlintide
Cagrisema (Cagrilintide + Semaglutide) (Fixed-combination amylin analog plus GLP-1 receptor agonist) and Pramlintide (Amylin analog) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Page updated 2026-09-20. Latest review of a source entry: 2026-09-20. Editorial method.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Cagrisema (Cagrilintide + Semaglutide) | Pramlintide |
|---|---|---|
| Compound class | Fixed-combination amylin analog plus GLP-1 receptor agonist | Amylin analog |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | Not documented | Not documented |
| Half-life | ~7 days (both components) | Not documented |
| Origin | An investigational fixed-dose combination developed by Novo Nordisk that co-formulates the amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide. It has been evaluated in clinical trials in the 2020s. | A 52-week randomized trial enrolled 656 insulin-treated people with type 2 diabetes and compared adjunctive pramlintide with placebo. The study assessed glucose control, body weight and adverse events. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Cagrisema (Cagrilintide + Semaglutide) works
CagriSema combines two complementary mechanisms in a single formulation: cagrilintide, a long-acting amylin analog acting on amylin/calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. The amylin component promotes satiety and slows gastric emptying, while the GLP-1 component enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite. The two are intended to act on distinct but complementary appetite- and glucose-regulating pathways.
How Pramlintide works
Pramlintide is an analog of amylin, a pancreatic hormone involved in post-meal glucose regulation. It is not a GLP-1 receptor agonist; it is grouped here for metabolic comparisons.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Cagrisema (Cagrilintide + Semaglutide)
Pramlintide
What sets each apart
Cagrisema (Cagrilintide + Semaglutide)
CagriSema is distinguished by being a fixed combination of an amylin analog and a GLP-1 agonist, rather than a single-molecule mono-, dual-, or triple-agonist.
Pramlintide
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
Frequently asked questions
What is CagriSema and what two compounds is it made of?
CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide, co-formulated for once-weekly administration. It pairs two distinct mechanisms — amylin/calcitonin-receptor signaling plus GLP-1-receptor signaling — in a single injection. It is studied in obesity and metabolic models where the combination showed larger weight effects than either component alone.
What is the ratio of cagrilintide to semaglutide in CagriSema?
The lead combination is a 1:1 ratio, CagriSema 2.4 mg / 2.4 mg — 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once weekly. Lower matched steps are used during escalation. In the REDEFINE 1 data the 2.4/2.4 mg combination produced greater mean weight reduction than either cagrilintide 2.4 mg or semaglutide 2.4 mg alone.
Why are the two components a good pharmacokinetic match?
Both cagrilintide (~7-8 day half-life) and semaglutide (~7 day half-life) are engineered for once-weekly dosing, so they can be co-administered on the same weekly schedule. Their similar kinetics are part of why the fixed-dose combination is practical. Study designs use a matched multi-week escalation for both components together.
What is the evidence context for Pramlintide?
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.
Linked publications
Publications recorded on each compound's profile, including original studies and reviews. These are background sources for the separate compounds; listing them together does not establish a direct comparison, a combination study, or equivalent evidence. Read the study design and limitations before interpreting a finding.
Cagrisema (Cagrilintide + Semaglutide)
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Source context on the Cagrisema (Cagrilintide + Semaglutide) profile